Judith Goldberg
Endocrinology · Greenwich, CTNPI 1912986571
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Amgen at 24.3% of the total. Reporting peaked in 2019 at $2,689 and has fallen 92.6% since, to $200 in 2025.
Across 229 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$521
- AstraZeneca$508
- Radius Health, Inc.$329
- Abbott$328
- Mannkind Corporation$311
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,93697%
- Education$1142%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 40 | $1,242 |
| Lilly USA, LLC | 35 | $521 |
| AstraZeneca(2 entities) | 23 | $508 |
| Radius Health, Inc. | 13 | $329 |
| Abbott | 13 | $328 |
| Mannkind Corporation | 7 | $311 |
| AbbVie | 15 | $258 |
| Novo Nordisk | 14 | $244 |
| Sanofi-aventis U.S. LLC | 11 | $193 |
| Boehringer Ingelheim | 9 | $180 |
| IBSA Pharma Inc. | 8 | $155 |
| Merck | 9 | $145 |
| Tandem Diabetes Care, Inc. | 2 | $139 |
| Arbor Pharmaceuticals, Inc. | 5 | $92 |
| Amneal Pharmaceuticals LLC | 4 | $86 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Exact Sciences | 1 | $34 |
| Johnson & Johnson | 2 | $34 |
| Ascensia Diabetes Care US Inc. | 2 | $33 |
| Mission Pharmacal Company | 2 | $26 |
| Corcept Therapeutics | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Insulet Corporation | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$526
- Tymlos$125
- AFREZZA$124
- Prolia$121
- FreeStyle Libre$120
- t-slim insulin pump$118
How this compares
Too few endocrinology providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $155,185 |
| TrulicityDulaglutide | 76 | $132,800 |
| MounjaroTirzepatide | 97 | $124,549 |
| FarxigaDapagliflozin Propanediol | 76 | $96,467 |
| JardianceEmpagliflozin | 62 | $81,949 |
| JanuviaSitagliptin Phosphate | 69 | $80,466 |
| SynthroidLevothyroxine Sodium | 454 | $40,639 |
| TradjentaLinagliptin | 15 | $23,099 |
| InvokanaCanagliflozin | 11 | $16,845 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $11,042 |
| Levothyroxine Sodium | 710 | $9,766 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $6,645 |
| Rosuvastatin Calcium | 334 | $6,636 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $6,014 |
| TirosintLevothyroxine Sodium | 16 | $5,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $521 | $257,349173 claims |
| Novo NordiskOzempic | $244 | $155,185127 claims |
| Boehringer IngelheimJardiance, Tradjenta | $180 | $105,04877 claims |
| AstraZenecaFarxiga | $508 | $96,46776 claims |
| MerckJanuvia | $145 | $80,46669 claims |
| AbbVieSynthroid | $258 | $40,639454 claims |
| Johnson & JohnsonInvokana | $34 | $16,84511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $86 | $9,766710 claims |
| IBSA Pharma Inc.Tirosint | $155 | $5,70716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other endocrinology in Greenwich
- Mary Kane-BrockGreenwich$0
- Marcos LamasDanbury$0
- Sonia HegdeNew Haven$0
- Elizabeth Sanchez RangelNew Haven$0
- Ana Luisa PerdigotoNew Haven$0
- Samuel DenglerNew London$0
- Priyadarshini BalasubramanianNew Haven$0
- Kasia LipskaNew Haven$0
- Jonathan BoganNew Haven$0
- Robert WeingoldNew Haven$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.